Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type

Neurology

Volumn 86, Issue 4, 2016, Pages 360-366

  Wilson, Duncan ^a,b,e   Charidimou, Andreas ^a,b,e   Shakeshaft, Clare ^b   Ambler, Gareth ^c   White, Mark ^b,d   Cohen, Hannah ^f   Yousry, Tarek ^b,d   Al Shahi Salman, Rustam ^g   Lip, Gregory Y H ^h   Brown, Martin M ^a,e   Jäger, Hans Rolf ^b,d   Werring, David J ^a,b,e  

^a Stroke Research Group   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Lysholm Department of Neuroradiology   (United Kingdom)

^e NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; C REACTIVE PROTEIN; DABIGATRAN; NON VITAMIN K ORAL ANTICOAGULANT AGENT; PROTHROMBIN; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN HEMORRHAGE VOLUME; BRAIN ISCHEMIA; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NERVOUS SYSTEM PARAMETERS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANKIN SCALE; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER; CHEMICALLY INDUCED; CLINICAL TRIAL; OUTCOME ASSESSMENT; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); WARFARIN;

EID: 84956724694     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002310     Document Type: Article

References (24)

1. Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817.
2. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 167-176.
3. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68: 116-121.
4. Lovelock CE, Molyneux AJ, Rothwell PM, Oxford Vascular S. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol 2007; 6: 487-493.
5. Bejot Y, Cordonnier C, Durier J, Aboa-Eboule C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain 2013; 136: 658-664.
6. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
7. Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 2012; 38: 7-15.
8. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012; 125: 165-170.
9. Lauer A, Cianchetti FA, Van Cott EM, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011; 124: 1654-1662.
10. Zhou W, Zorn M, Nawroth P, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
11. Hagii J, Tomita H, Metoki N, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke 2014; 45: 2805-2807.
12. Charidimou A, Shakeshaft C, Werring DJ. Cerebral microbleeds on magnetic resonance imaging and anticoagulantassociated intracerebral hemorrhage risk. Front Neurol 2012; 3: 133.
13. Volbers B, Staykov D, Wagner I, et al. Semi-automatic volumetric assessment of perihemorrhagic edema with computed tomography. Eur J Neurol 2011; 18: 1323-1328.
14. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32: 1318-1322.
15. Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59: 421-437.
16. Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63: 1338-1347.
17. Friedman PA, Rosenberg RD, Hauschka PV, Fitz- James A. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 1977; 494: 271-276.
18. Malhotra OP, Nesheim ME, Mann KG. The kinetics of activation of normal and gamma-carboxyglutamic aciddeficient prothrombins. J Biol Chem 1985; 260: 279-287.
19. Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs 2007; 16: 431-440.
20. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010; 30: 376-381.
21. Wilson D, Charidimou A, Werring DJ. Advances in understanding spontaneous intracerebral hemorrhage: insights from neuroimaging. Expert Rev Neurother 2014; 14: 661-678.
22. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project-1981-86: 2: incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53: 16-22.
23. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
24. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep 2014; 16: 480.